

Case Docket No. WWELL52.001APC

Date: November 19, 2004

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s)

Brossart, et al.

Appl. No.

10/019,513

Filed

August 6, 2002

For

PEPTIDE FOR TRIGGERING

AN IMMUNE REACTION AGAINST TUMOR CELLS

Examiner

Ungar, Susan

Group Art Unit:

1642

I hereby certify that this correspondence and all marked attachments are being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Mail Stop Amendment, P.O. Box 1450, Alexandria, VA 22313-1450, on

November 19, 2004

Che Swyden Chereskin, Ph.D., Reg. No. 41,466

TRANSMITTAL LETTER

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

Enclosed for filing in the above-identified application are:

- (X) An Information Disclosure Statement.
- (X) A PTO Form 1449 with six (6) references.
- The Commissioner is hereby authorized to charge any additional fees which may be required, or (X) credit any overpayment, to Account No. 11-1410.
- (X)Return prepaid postcard.

Che Swyden Chereskin, Ph.D.

Registration No. 41,466 Agent of Record

Customer No. 20,995

(949) 760-0404

NOV 2 2 2004

INFORMATION DISCLOSURE STATEMENT

Applicant : Brossart, et al.

App. No. : 10/019,513

Filed: August 6, 2002

For : PEPTIDE FOR TRIGGERING AN IMMUNE

REACTION AGAINST TUMOR CELLS

Examiner : Ungar, Susan

Group Art Unit : 1642

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

Enclosed is form PTO-1449 listing 6 references that are also enclosed.

This Information Disclosure Statement is being filed before the mailing date of a final action under 37 C.F.R. § 1.113 and before the mailing date of a Notice of Allowance under § 1.311. A certification under 37 C.F.R. § 1.97(e) is set forth below. Thus, no fee is required as set forth in 37 C.F.R. § 1.97(c).

CERTIFICATION UNDER 37 C.F.R. § 1.97(e)(1)

I hereby certify that each item of information contained in this Statement was first cited in a communication from a foreign Patent Office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: 150.19 2004

Che Swyden Chereskin, Ph.D.

Registration No. 41,466

Agent of Record

Customer No. 20,995

(949) 760-0404

H:\DOC\$\C\$C\C\$C-8192.DOC\111704

SI	н	F	F٦	1	(١F	

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRANSPORTED SPICE	ATTY. DOCKET NO. WWELL52.001APC	APPLICATION NO. 10/019,513
BY APPLICANT HOV 2 2 2004	APPLICANT Brossart, et al.	
(USE SEVERAL SHEETS IF NEW SSARY)	FILING DATE August 6, 2002	GROUP 1642

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)

FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	WO 98/50527	11/12/98	PCT				
	WO 97/11715	4/3/97	PCT				
	WO 00/06723	2/10/00	PCT				
	DE 195 16 673 A1	10/31/96	Germany			Abstract	

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)						
	Brossart, et al. "Identification of HLA-A2-Restricted T-Cell Epitopes Derived from the MUC1 Tumor Antigen for Broadly Applicable Vaccine Therapies," Blood, Vol. 93, No. 12, pp. 4309-4317, June 15, 1999. European Search Report completed on October 4, 2004 and issued to a related foreign application.						
}							

H:\DOCS\CSC\CSC-8193.DOC 111704

FXAM	HAILD